Robert Langreth is a senior reporter at Bloomberg News, specializing in science and health reporting. With a wide range of publications featuring his work, including Bloomberg Law, The Washington Post, and The Sydney Morning Herald, Langreth covers topics such as pharmaceutical companies, drug industry trends, and breakthroughs in medical research. His articles provide in-depth analysis and insights into the business and science behind the healthcare industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Robert Langreth's coverage predominantly focuses on the healthcare and pharmaceutical industry. He often cites data, press releases, and government announcements in his articles. To effectively reach out to him, consider providing fact-based insights supported by relevant data or official announcements related to the pharmaceutical industry.
Given his focus on specific companies and drug-related topics such as cancer drugs, weight loss drugs, Parkinson's cure, Alzheimer's research, etc., experts with direct knowledge of these areas would be valuable sources for Robert's articles.
While there is no specified geographic focus for Robert Langreth’s reporting based on the available information provided about his article titles and coverage attributes; however it seems that he has a global perspective when covering healthcare and pharmaceutical topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Matthew Monks, Robert Langreth, Crystal Tse
Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a pipeline of new potential blockbusters.
Pfizer Inc. raised its guidance for the year as it reported adjusted earnings that beat expectations in its first quarterly report since its standoff with activist investor Starboard Value LP became public.
Merck & Co. lowered the top end of its full-year sales guidance after demand for its HPV vaccine fell for a second straight quarter in China.
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
Hi, it’s Bob in New York. The rash that appeared on my arm in June was astonishingly itchy, and no one could figure out what caused it. But first …
By: Robert Langreth, Madison Muller
Amgen Inc.’s experimental obesity shot helped patients lose up to 20% of their body weight over a year, in results from a highly-anticipated trial that also tested if the drug could be taken less frequently than popular weight-loss drugs made by Novo Nordisk A/S and Eli Lilly & Co.
By: Madison Muller, Robert Langreth
Amgen Inc. shares fell after its experimental obesity shot helped patients lose up to 20% of their body weight in a yearlong trial, disappointing investors who had hoped the highly anticipated trial would produce more weight loss.
President elect Donald Trump nominated health policy researcher Jay Bhattacharya to head the US National Institutes of Health, the sprawling agency that oversees close to $50 billion in basic biomedical research spending.
By: Robert Langreth
President elect Donald Trump nominated health policy researcher Jay Bhattacharya to head the US National Institutes of Health, the sprawling agency that oversees close to $50 billion in biomedical research spending.
By: Robert Langreth
Bloomberg: President elect Donald Trump nominated health policy researcher Jay Bhattacharya to head the US National Institutes of Health, the sprawling agency that oversees close to $50 billion in biomedical research spending. Bhattacharya, a health economist and doctor at Stanford University, is best known as one of the three authors of an October 2020 […]
(833) 317-6278 
